Skip to content


We are devoted to providing accurate, affordable, and non-invasive liquid biopsy tests for early cancer detection and precision medicine.

Who We Are

Xiaohui Ni, Ph.D.

Chief Technology Officer

Lara Baden

Vice President of Laboratory Operations

Jim Liu, Ph.D.

Chief Computing Officer

Stephen Terry

Chief Financial Officer

Mary Stackpole, Ph.D.

Vice President in Bioinformatics

Jasmine Zhou, Ph.D., Co-founder and co-CEO

Dr. Zhou is a co-founder of EarlyDx and a Professor of Pathology and Lab Medicine at UCLA. She has an extensive publication record in bioinformatics, big data analytics, and liquid biopsy diagnostics. She is currently leading the NIH-funded UCLA Center for the Early Detection of Liver Cancer. She previously served as the Head of Computational Biology program at University of Southern California. She is a recipient of NSF CAREER Award and Alfred Sloan Fellowship. She holds a Diplom in Biochemistry from University of Tubingen (Germany), and a Nachdiplom in Computer Science and a Ph.D. in Bioinformatics from the Swiss Federal Institute of Technology. She completed her postdoctoral training in Biostatistics at Harvard University.

Gregory Critchfield, M.D., Co-CEO

Dr. Critchfield brings decades of experience in the diagnostics industry, including a proven track record of successfully launching diagnostics products and significantly growing revenues for leading diagnostics companies. As a board member, former chairman and CEO, he led Sera Prognostics from its very early financing stages in 2010 through and beyond its successful IPO in 2021.  Before Sera, he was President of Myriad Genetic Laboratories, a wholly-owned subsidiary of Myriad Genetics, Inc., building Myriad into one of the leading molecular diagnostics companies in the world.  Prior to Dr. Critchfield’s role at Myriad, he served as Senior Vice President, Chief Medical and Science Officer of Quest Diagnostics (formerly Corning Clinical Laboratories). Before Quest Diagnostics, Dr. Critchfield was the Director of Clinical Pathology at Intermountain Health Care. He has served on the boards of more than ten molecular diagnostics, biopharmaceutical and medical device companies.

Wing Hung Wong, Ph.D., Co-founder

Dr. Wong is a co-founder of EarlyDx and the Stephen R. Pierce Family Goldman Sachs Professor at Stanford University. Dr. Wong is a world-renowned statistician and biomedical data scientist. He made significant contributions to statistical methods and computer programs for the analysis of data from next-generation sequencing, especially in the area of gene regulation. Dr. Wong is a member of the National Academy of Sciences. He won the highest award in the field of Statistics (the COPSS Presidential Award). He previously served as the Head of Statistics Department at Stanford University. Dr. Wong co-founded the big data company Bina Biotechnologies, acquired by Roche in 2014. Dr. Wong received his B.S. in Mathematics from the UC Berkeley, and his Ph.D. in Statistics from the University of Wisconsin.

Peter Li, Ph.D., Co-founder

Dr. Li is a co-founder of EarlyDx and an Adjunct Associate Professor at UCLA. His research focuses on machine learning, biomedical informatics, and clinical informatics of liquid biopsy. Dr. Li has developed a series of computational methods and software to analyze and integrate biomedical data, including biological networks, multi-omics data, and 3D structural data of genomes. He currently serves as a Principle Investigator of multiple NIH-funded grants on liquid biopsy. Dr. Li received his Ph.D. in computer science from Nanyang Technological University (Singapore) and completed his postdoctoral training in Computational Biology at the University of Southern California.

Xiaohui Ni, Ph.D., Chief Technology Officer

Xiaohui is the Chief Technology Officer of EarlyDx. Xiaohui has 20+ years of experience in research and product development. He received interdisciplinary research training across physics, molecular biology, and cancer genomics. Prior to EarlyDx, he was a senior scientist at Cynvenio Biosystems (now LungLife AI). He was the main contributor to Cynvenio’s FISH test in lung cancer early detection using circulating tumor cells in the blood. Xiaohui leads EarlyDx’s NIH SBIR award on assay development. Xiaohui received his Ph.D. in Physics from the City University of New York and completed his postdoctoral training in Cancer Genomics at Harvard University.

Lara Baden, Vice President of Laboratory Operations

Lara Baden serves as the Vice President of Laboratory Operations at EarlyDiagnostics, Inc., where she provides strategic leadership and oversight for the company’s clinical laboratory operations. In this role, Lara is responsible for driving excellence in laboratory performance, ensuring compliance with CLIA/CAP regulations, and spearheading clinical studies initiatives.

With over 20 years of diverse laboratory experience, Lara is a California Licensed Clinical Genetic Molecular Biologist Scientist. She joined EarlyDiagnostics, Inc. after a successful tenure at LungLife AI (previously Cynvenio) in 2016, where she held the position of VP of Clinical Lab Operations. During her time at LungLife AI, Lara brought extensive regulatory and compliance expertise to the lab, ensuring adherence to industry standards and best practices. 

Lara is known for her strong interpersonal skills and her ability to effectively manage and motivate teams. She is dedicated to maintaining the highest quality standards while optimizing operational efficiency and controlling costs. Lara is passionate about building collaborative teams and mentoring colleagues to foster professional growth and development.

Prior to her role at LungLife AI, Lara spent 15 years at Cedars-Sinai Medical Center, where she held multiple leadership positions within the laboratory. She earned her Bachelor of Science degree in Biochemistry from the University of California, Los Angeles (UCLA).

Jim Liu, Ph.D., Chief Computing Officer

Jim is the Chief Computing Officer at EarlyDx. Prior to EarlyDx, he was an associate professor at National Chung Hsing University (Taiwan) and led the development of a wide range of Bioinformatics methods, software, and databases. Jim has over 20+ years of experience in bioinformatics, machine learning, and software/hardware architectures, and has published 40+ journal papers. He has constructed more than 10 publicly available biomedical databases. Jim received his Ph.D. in Bioinformatics from National Chung Hsing University and completed his postdoctoral training in Computational Biology at the University of Southern California.

Stephen Terry, Chief Financial Officer

Stephen is the Chief Financial Officer of EarlyDx. Stephen has more than 25 years in finance with particular expertise in supporting growth-stage technology companies with scaling their operations, including international expansion. Prior to EarlyDx, he served as CFO of several early-stage, venture-backed technology companies which experienced successful exits. Stephen received his Bachelor of Science in Materials Science and Engineering from the Massachusetts Institute of Technology and is a CFA Charterholder.

Mary Stackpole, Ph.D., Vice President in Bioinformatics

Mary is the Vice President of Bioinformatics at EarlyDx. She is an expert in NGS data analysis and liquid biopsy technologies. She was a major contributor to the CancerRadar test for early cancer detection. She has 5+ years of experience in liquid biopsy and assay informatics. Mary received double bachelor’s degrees in Biology and Mathematics from the University of Maryland, an M.S. in Statistics from the University of Southern California, and a Ph.D. in Bioinformatics from UCLA.